Research Analysts Set Expectations for CRSP FY2025 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Leerink Partnrs boosted their FY2025 earnings estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Tuesday, February 11th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($5.16) for the year, up from their previous forecast of ($5.53). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.08) per share.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%.

Other analysts also recently issued reports about the stock. Morgan Stanley raised their price objective on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a research report on Friday. Royal Bank of Canada decreased their price objective on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research report on Wednesday. Stifel Nicolaus reduced their price target on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a report on Thursday. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a report on Thursday. Finally, Truist Financial lifted their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $74.50.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $49.72 on Friday. The stock has a market capitalization of $4.26 billion, a PE ratio of -17.57 and a beta of 1.67. CRISPR Therapeutics has a 1-year low of $36.52 and a 1-year high of $91.10. The company’s fifty day simple moving average is $41.89 and its 200-day simple moving average is $46.17.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. This represents a 7.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Northern Trust Corp increased its stake in CRISPR Therapeutics by 12.9% during the 4th quarter. Northern Trust Corp now owns 257,168 shares of the company’s stock valued at $10,122,000 after purchasing an additional 29,416 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $3,636,000. Virtus ETF Advisers LLC boosted its holdings in shares of CRISPR Therapeutics by 52.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 7,702 shares of the company’s stock valued at $303,000 after acquiring an additional 2,655 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in shares of CRISPR Therapeutics by 39.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock valued at $150,029,000 after acquiring an additional 1,074,238 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of CRISPR Therapeutics by 3.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 24,563 shares of the company’s stock valued at $967,000 after acquiring an additional 800 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.